Atea Pharmaceuticals SEC filings document the regulatory record of a Nasdaq-listed clinical biopharmaceutical company developing oral antiviral therapies. Form 8-K reports furnish financial results, preliminary financial information, business updates, and exhibit press releases that describe the company’s HCV and HEV antiviral programs.
Proxy and annual meeting filings cover governance matters, director elections, auditor ratification, executive compensation, pay-versus-performance disclosures, and stockholder voting results. The filings also identify Atea’s common stock, par value $0.001 per share, traded under AVIR on The Nasdaq Global Select Market.
Form 4 filing (24-Jun-2025) reveals that Atea Pharmaceuticals (AVIR) director Franklin M. Berger increased his ownership through equity-based compensation granted on 20-Jun-2025. A total of 29,600 previously issued restricted stock units (RSUs) vested and converted into common shares (Code M) at a $0.00 cost, lifting his direct holdings to 506,497 shares. Concurrently, Berger received 29,600 new RSUs that will vest at the next annual meeting or one-year anniversary, and 41,200 stock options with a $3.25 exercise price expiring 19-Jun-2035, vesting monthly over 12 months. No shares were sold. The transactions signal net insider accumulation while introducing modest potential dilution through the new RSUs and options.
Form 4 highlights for Atea Pharmaceuticals, Inc. (AVIR)
- Reporting person: Bruce Polsky, Director.
- Transaction date: 20 Jun 2025; filing date 24 Jun 2025.
- Non-derivative shares: 29,600 common shares acquired at $0.00 upon RSU vesting; total direct ownership now 95,206 shares.
- New derivative grants:
- 29,600 Restricted Stock Units (RSUs) that vest on the earlier of the 2026 annual meeting or 1-year anniversary of grant.
- 41,200 stock options with a $3.25 exercise price, vesting monthly over 12 months and expiring 19 Jun 2035.
- Derivative disposition: 29,600 RSUs converted to common stock (code “M”), leaving zero balance for that award.
The filing reflects routine director equity compensation—no open-market buying or selling—and increases Mr. Polsky’s direct equity stake in AVIR. No cash outlay was required for the RSU conversion; the new option strike establishes the cost basis for potential future purchases.
Form 4 highlights for Atea Pharmaceuticals (AVIR): Director Jerome M. Adams reported several equity transactions on 20 June 2025.
- Common shares acquired: 29,600 shares were received upon conversion of previously vested restricted stock units (RSUs) at an effective price of $0.00 (code M). Adams now holds 62,750 AVIR shares directly.
- New equity awards granted:
- RSUs: 29,600 units granted (code A). They vest in a single installment on the earlier of the next annual meeting or the first anniversary of grant, subject to continued service.
- Stock options: 41,200 options granted with a $3.25 exercise price, expiring 19 June 2035. Vest monthly over 12 months, fully vested after one year.
- No derivative securities were sold; 29,600 RSUs were converted and the related derivative position is now zero.
Overall, the director increased his direct equity stake and received additional incentive-based awards, signaling continued alignment with shareholder interests.
Atea Pharmaceuticals (AVIR) filed a Form 4 on 24 Jun 2025 for director Bruno Lucidi covering transactions dated 20 Jun 2025.
- Common stock acquired: 29,600 shares were issued upon the full vesting and conversion of previously granted restricted stock units (RSUs) at a cost of $0, raising Lucidi’s direct holdings to 112,750 shares.
- New equity grants: (i) 29,600 RSUs that vest in a single tranche on the earlier of the next annual shareholder meeting or the first anniversary of grant; (ii) 41,200 stock options with a $3.25 exercise price, vesting in 12 equal monthly installments through 20 Jun 2026 and expiring on 19 Jun 2035.
- No open-market purchases or sales were reported; all activity reflects equity incentive awards and conversions.
The filing indicates continued insider equity ownership alignment, with a modest increase in direct share count and fresh long-term option incentives.
A Form 4 filed for Atea Pharmaceuticals, Inc. (AVIR) discloses that director Howard Berman received a new equity incentive award on 20 June 2025. The filing reports the grant of a stock option to purchase 164,800 shares of common stock at an exercise price of $3.25 per share. The option vests in 36 equal monthly installments beginning on the grant date and will be fully vested on 20 June 2028. It carries an expiration date of 19 June 2035. No acquisitions or dispositions of common shares were reported in Table I; the entire award is recorded in Table II as a derivative security held directly (Form D ownership). Following the grant, Berman’s reported beneficial ownership consists of 164,800 derivative securities tied to common stock. The transaction is coded “A,” indicating an award rather than a market purchase or sale.